Medical Assistance
Receive guidance from the first consultation through the entire hospitalization process.
0
Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
0 Vote
1 Contributor
1286 Views 
0 Saved 0 Vote 1 Contributor1286 Views 0 SavedYou might also be interested in
According to many studies, breast cancer is more common in women whose family members or blood relatives have also had breast cancer. This means that it is mostly genetic. Other factors like Radiation exposure, obesity, alcohol consumption, not having children, can all participate as risk factors fo....
There are several persistent internet rumours about potential causes of breast cancer. One is that wearing a bra, or wearing an underwire bra, causes the disease. The idea that bras may cause cancer was fuelled by the 1995 book called Dressed to Kill by Sydney Ross Singer and Soma Grismaijer. It cla....
Homeopathy is one of the most common complementary therapies used by people with cancer. Although there have been many research studies into homeopathy there is no scientific or medical evidence that it can prevent cancer or work as a cancer treatment. Homeopathy is based on the theory of trea....
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.